Vicore Pharma Holding AB (publ) announced pipeline updates as the company continues to focus on development of C21 for idiopathic pulmonary fibrosis (IPF). The updates announced include confirmation that development of the lead program, C21 for IPF is on track, with final Phase 2a AIR data in the first half of next year. In addition, start-up activities for the global, double-blind, placebo-controlled, 52-week, Phase 2b ASPIRE study of C21 for IPF are progressing with initiation expected in the first half of 2024.

Development of the Almee digital therapy advances as well, with topline results of the COMPANION pivotal study for anxiety associated with pulmonary fibrosis expected to be reported in January 2024. In its early-stage pipeline, as a result of an on-going portfolio review process that aims to focus investments, Vicore will discontinue development of the preclinical IMiD program, inhaled thalidomide for IPF cough. The review is also expected to select the best possible follow-on indications and ATRAG molecules for further development in view of the unique characteristics of this upstream mechanism of action that drives tissue repair.